NCT05772520

The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis

A Randomized, Double-blinded, Placebo-controlled, Multicenter Phase 2 Study Evaluating the Efficacy and Safety of TLL018 in Participants With Moderate-to-severe Plaque Psoriasis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 82 (actual)
• Sponsor: Hangzhou Highlightll Pharmaceutical Co., Ltd · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase 2, multicenter, randomized, double-blinded, parallel dose group, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of 2 doses of TLL018 as therapy in approximately 90 participants with moderate-to-severe PP.

Conditions

• Plaque Psoriasis

Interventions

Type	Name	Description
DRUG	TLL018 tablets	oral tablets administered 20 mg BID and 40 mg BID for 12 weeks

Timeline

• Start date: 2023-01-19
• Primary completion: 2024-12-01
• Completion: 2024-12-23
• First posted: 2023-03-16
• Last updated: 2024-12-27

Locations

35 sites across 1 country: United States

Regulatory

• FDA-regulated drug study